Hercules Capital Closes $2.3 Billion Across Two Private Credit Vehicles

Hercules Capital's registered investment adviser, Hercules Adviser LLC, closed two institutional private credit vehicles in September 2026, raising a combined $2.3 billion in investable capital, Alternative Credit Investor reported on September 9. The two vehicles are the Hercules Evergreen Fund, a perpetual open-end structure, and Hercules Growth Lending IV, a closed-end platform, both targeting growth-stage technology and life sciences companies. The firm simultaneously closed a rated securitisation, drawing commitments from insurance companies, pension funds, asset managers, foundations, endowments, and family offices across the globe. For anyone tracking private credit allocations, this raise from the largest non-bank venture lender in the U.S. is worth a careful look at what the structure means, what the market context tells you, and where the risks sit.

Two Funds, One Platform, and $2.3 Billion

The raise does not materialize out of nowhere. Hercules Adviser LLC was established in 2021 as a wholly owned subsidiary of Hercules Capital and a registered investment adviser, built specifically to manage institutional private funds that operate alongside the publicly traded BDC. Growth Lending IV is the fourth fund in that series. The Evergreen Fund is the platform's first perpetual vehicle, representing a structural expansion into a format that LPs across the private credit space have increasingly demanded.

Hercules Capital, Inc. (NYSE: HTGC) has been a publicly traded business development company since it listed in 2005. Together with Hercules Adviser, the combined platform now manages approximately $6.1 billion in assets. Since its founding in 2003, Hercules has committed more than $28 billion to over 700 companies, according to the firm's official platform disclosures, placing it at the top of the non-bank venture lending market by cumulative capital deployed.

The two new vehicles address clearly different LP objectives. Hercules Growth Lending IV follows the closed-end model that institutional allocators have used for decades: a defined fund life, a finite capital raise with a hard close, and a return-of-capital timeline tied to loan maturities and exits. The Hercules Evergreen Fund operates on a perpetual basis with no fixed end date, allowing investors to commit capital on an ongoing basis and participate in Hercules' lending activity without locking into a finite term. Scott Bluestein, Hercules' chief executive and chief investment officer, described the evergreen vehicle as "a permanent capital avenue to invest alongside Hercules and our closed-end vehicles in financing the most innovative growth-stage technology and life sciences companies in the world."

One detail the primary reporting does not break out is the individual capital split between the two vehicles. The $2.3 billion figure covers both Growth Lending IV and the Evergreen Fund combined, plus the rated securitisation. If you are an LP deciding which vehicle fits your mandate, you will want to see the individual fund sizes in formal offering documents or future SEC-related filings before making an allocation decision.

The BDC Foundation That Makes This Possible

To understand how Hercules assembles $2.3 billion in a single round, you need to understand the BDC structure beneath the platform. Congress created business development companies in 1980 to give investors a regulated path into private company financing. BDCs must distribute at least 90% of their taxable income to shareholders each year, which creates a predictable income stream. They also file quarterly reports with the SEC, providing a level of transparency that most private credit funds simply do not offer.

Hercules Capital is not a generalist BDC. The firm concentrates its lending on venture-backed technology and life sciences companies at the expansion and growth stages, targeting a roughly 50/50 allocation between the two sectors in its loan portfolio. Its debt is structured primarily with warrants attached, giving the firm equity upside to compensate for lending to pre-profitability borrowers. Effective yields on Hercules' portfolio reached 13.4% in Q2 2026, according to Axis Intelligence research on BDC public filings, with 97.8% of the debt portfolio carrying floating rates tied to the prime rate or SOFR.

That two-decade track record of sector-specific underwriting is what lets Hercules attract the caliber of institutional LPs, insurers, pension funds, family offices, that closed the two new vehicles. Generalist lenders do not build that kind of LP trust in growth-stage biotech or pre-revenue SaaS. Hercules has, and the Adviser platform is now the vehicle for channeling that credibility into institutional private fund commitments beyond the public BDC.

Evergreen vs. Closed-End: What the Structure Really Means for Your Allocation

If you are an LP evaluating a commitment to either vehicle, the structural choice deserves the same scrutiny as the underlying credit strategy. These are not interchangeable.

A closed-end fund like Growth Lending IV operates on a defined timeline. Capital is called over an investment period, loans are originated and held, and the fund winds down as loans mature or are sold, returning proceeds to LPs in a predictable sequence. You have a rough sense of when capital comes back. The trade-off is inflexibility: early exits require selling your position on a secondary market, and secondary liquidity for private credit fund interests can be thin, particularly during market stress.

An evergreen fund works differently. No fixed end date. The fund raises capital on a continuous basis, deploys it into loans, and recycles repaid principal into new originations. LPs can typically subscribe or redeem at defined intervals, often monthly or quarterly, at net asset value (NAV). Law firm Loyens and Loeff published a detailed structuring guide in March 2026 on evergreen private credit fund structures that describes these vehicles as "semi-liquid," because they must balance investor redemption requests against the inherently illiquid nature of private loans. Redemption windows are generally capped at a fixed percentage of NAV per quarter to prevent forced asset sales that would damage remaining investors.

The institutional demand is real. Research from Preqin shows the count of evergreen private credit funds has more than doubled over the past five years, driven by pension funds and insurance companies that want continuous exposure to private credit without re-underwriting a new fund commitment every three to five years. For a pension fund matching liabilities over a rolling twenty-year horizon, a perpetual vehicle lets capital stay continuously deployed rather than sitting idle between fund vintages.

The complexity trade-off is real too. Carta's analysis of evergreen fund mechanics notes that managers must hold enough liquid assets to meet potential redemptions, which can dilute portfolio returns if the cash buffer grows large. During market stress, when redemption requests spike precisely when underlying loans are hardest to sell, gate mechanisms can activate and lock LPs in longer than they planned. The perpetual label does not mean perpetual access to your capital.

The Market Behind the Raise

Hercules closed $2.3 billion into a market that has grown dramatically over the past three years. U.S. venture debt reached a record $68.8 billion in 2025 across roughly 1,046 deals, per the Runway Growth Venture Debt Review 2025-2026. That total more than doubled from $29.2 billion in 2023, even as deal count edged down from 1,108 transactions over the same period. Fewer borrowers are receiving much larger facilities, which tells you the growth is coming from quality, not quantity.

Q1 2026 continued that pattern: $19.7 billion in new venture debt across 126 loans, with the average deal size reaching $156.3 million, a more than tenfold increase from $14.0 million a decade earlier, according to Axis Intelligence's analysis of PitchBook-NVCA Venture Monitor data. Technology companies captured 98% of venture debt dollars that quarter. Hercules itself recorded $2.74 billion in new loan commitments in the first half of 2026, up 35.6% year over year, with commitments growing far faster than gross fundings, a sign that borrowers are signing credit facilities but not drawing them fully, reserving capacity for future needs.

PitchBook research shows late-stage venture debt hit decade highs in Q1 2026, with the median late-stage deal reaching $10.8 million and the average climbing to $68.2 million. The mechanism is straightforward: founders at high valuations find equity expensive. Selling shares at current valuations means heavy dilution for existing shareholders. Venture debt lets companies extend runway, fund working capital, or bridge to a milestone without surrendering ownership. Hercules is the market's most experienced underwriter of that trade.

Four Risks Worth Taking Seriously

I find the growth-lending thesis compelling, but you should go in clear-eyed on four specific risks.

Borrower credit risk is the starting point. Life sciences companies at the growth stage often have no revenue. The lender underwrites the probability of a next equity round, not current cash flow. When equity markets concentrate elsewhere, that underwriting breaks down. Axis Intelligence data shows healthcare venture debt fell to $0.4 billion across just 18 loans in Q1 2026, down from $7.1 billion across 192 loans in all of 2025, largely because equity was flooding AI rather than biotech. Hercules maintains a dedicated life sciences book, which creates upside when the sector is open and real credit exposure when it is not.

Liquidity risk inside the evergreen vehicle is the second concern. A perpetual structure sounds appealing until you need to exit during market stress. Redemption gates protect the fund from fire-sale asset liquidations but they protect it at your expense. If a large cohort of LPs requests redemptions simultaneously, the gate activates and you remain invested through the cycle you were trying to exit.

Interest rate compression is already showing up in lender data. Effective yields at Hercules ran 13.4% in Q2 2026, but front-book onboarding yields across the sector have been falling. Horizon Technology Finance, a publicly traded peer lender, reported onboarding yields of 12.0% in Q2 2026 against a back-book portfolio yield of 14.9%, a 290-basis-point gap between what new loans price at and what the existing portfolio earns. Competition among lenders is compressing new origination yields even as the headline portfolio yield looks strong.

Sector concentration is the fourth. Both vehicles focus on growth-stage technology and life sciences borrowers. Those sectors tend to move together through venture cycles. If the venture-backed equity market stalls broadly across both sectors, the next-round underwriting that supports Hercules' credit decisions becomes harder across the whole portfolio at the same time, not in isolated pockets that offset each other.

For more on this, see our related coverage:

• Wall Street Built Two Evergreen Fund Structures. Institutions Got the Illiquid One. Retail Got the Redemption Gate.
• PIK Loans in Private Credit: What Payment-in-Kind Notes Mean for Direct Lending Investors

Frequently Asked Questions

What is Hercules Adviser LLC, and how does it differ from Hercules Capital (NYSE: HTGC)?

Hercules Capital, Inc. (NYSE: HTGC) is a publicly traded business development company that has filed quarterly disclosures with the SEC since listing in 2005 and is accessible to any investor who can buy a stock. Hercules Adviser LLC is a registered investment adviser founded in 2021 as a wholly owned subsidiary, created specifically to manage institutional private funds outside the public BDC structure. The Evergreen Fund and Growth Lending IV are products of Hercules Adviser, requiring LP commitments to private vehicles with high minimum thresholds rather than buying exchange-traded shares.

Who qualifies to invest in the Hercules Evergreen Fund or Growth Lending IV?

Both vehicles target global institutional investors including insurance companies, pension funds, asset managers, foundations, endowments, and family offices. They carry minimum commitment thresholds typical of institutional private credit funds and are not available to retail investors. If you do not qualify as a qualified purchaser under SEC definitions, you cannot access these vehicles directly, though you may gain indirect exposure through institutional allocators that hold positions in them.

What does the rated securitisation closed alongside the two funds mean for the platform?

A rated securitisation packages existing loans from Hercules' portfolio into structured notes sold to outside investors, typically insurers or other yield-focused institutions that require an independent credit rating on the instrument. The sale proceeds recycle back into new loan originations, accelerating capital deployment without waiting for existing loans to mature. The credit rating reflects an assessment of the collateral pool, not a guarantee against loss, and if underlying loans underperform the collateral quality, the structure can restrict the platform's operational flexibility at an inopportune time.

How does venture debt differ from traditional bank lending for growth-stage companies?

Traditional bank lending requires positive cash flow, tangible collateral, and operating-account deposit covenants that constrain a company's treasury. Venture debt, as Hercules explains in its investor FAQ, is available to companies without positive cash flow or hard assets, underwritten on venture capital backing, intellectual property value, and the probability of reaching future milestones. Lenders price that higher risk into rates and attach warrants to capture equity upside alongside interest income.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.